You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Biological Activity for Aspirin
Aspirin is an inhibitor of cyclooxygenase (COX)-1. Blocks the production of prostaglandins and thromboxanes. Exhibits antiplatelet and antithrombotic activities. Displays anticancer effects in some solid tumors. One of the first described NSAID drugs.
Compound Libraries for Aspirin
Technical Data for Aspirin
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for Aspirin
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions for Aspirin
The following data is based on the product molecular weight 180.16. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||5.55 mL||27.75 mL||55.51 mL|
|5 mM||1.11 mL||5.55 mL||11.1 mL|
|10 mM||0.56 mL||2.78 mL||5.55 mL|
|50 mM||0.11 mL||0.56 mL||1.11 mL|
References for Aspirin
References are publications that support the biological activity of the product.
Schror (1997) Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis. Semin.Thromb.Hemost. 23 349 PMID: 9263351
Sanduja et al (1991) Aspirin inhibits interleukin 1-induced prostaglandin H synthase expression in cultured endothelial cells. Proc.Natl.Acad.Sci. 15 88
Baron (1995) Aspirin and cancer. Preventative Medicine 24 121
If you know of a relevant reference for Aspirin, please let us know.
View Related Products by Product Action
Keywords: Aspirin, Aspirin supplier, cyclooxygenase, inhibitors, inhibits, antithrombotic, antiplatelet, NSAID, prostaglandin, H, synthase, blocks, thromboxane, synthesis, Cyclooxygenase, 4092, Tocris Bioscience
2 Citations for Aspirin
Citations are publications that use Tocris products. Selected citations for Aspirin include:
Walsh et al (2014) The role of Nox1 and Nox2 in GPVI-dependent platelet activation and thrombus formation. Redox Biol 2 178 PMID: 24494191
Mitrugno et al (2014) A novel and essential role for FcγRIIa in cancer cell-induced platelet activation. Blood 123 249 PMID: 24258815
Do you know of a great paper that uses Aspirin from Tocris? Please let us know.
Reviews for Aspirin
There are currently no reviews for this product. Be the first to review Aspirin and earn rewards!
Have you used Aspirin?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.